AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31199090 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg voxelotor
Number of subjects: 274
Study 31199090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 28202260 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (Group A)
Number of subjects: 8047
Study 28202260 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone (Group B)
Number of subjects: 8047
Study 28202260 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Group A/B)
Number of subjects: 8047
Study 28202260 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (over 270 DDDs)
Number of subjects: 8047
Study 28202260 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone (over 360 DDDs)
Number of subjects: 8047
Study 25616485 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive neurostimulation (RNS System)
Number of subjects: 230
Study 23412403 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite ceramic graft hydrated with bone marrow aspirate (group 1)
Number of subjects: 32
Study 23412403 — intervention group
Group type: COMPARATOR
Intervention: Composite ceramic graft alone without bone marrow aspirate (group 2)
Number of subjects: 32
Study 22018993 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS)
Number of subjects: 32
Study 18289333 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glycolic acid (GA)
Number of subjects: 20
Study 18289333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18289333 — intervention group
Group type: COMPARATOR
Intervention: Occlusive dressing
Number of subjects: 20
Study 16519969 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line discussions
Number of subjects: 0
Study 16519969 — intervention group
Group type: COMPARATOR
Intervention: Traditional group discussions
Number of subjects: 0
Study 12946754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative planning using a Mick applicator
Number of subjects: 300
Study 12946754 — intervention group
Group type: COMPARATOR
Intervention: Preplanning using preloaded needles
Number of subjects: 300
Study 12946754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 300
Study 12946754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative method
Number of subjects: 300
Study 11143776 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor, ramipril
Number of subjects: 0
Study 9292644 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 151
Study 9292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacridine lactate
Number of subjects: 151
Study 9292644 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2+oxytocin infusion
Number of subjects: 151
Study 9292644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacridine lactate+oxytocin infusion
Number of subjects: 151
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: Total resection
Number of subjects: 645
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection
Number of subjects: 645
Study 8387988 — intervention group
Group type: COMPARATOR
Intervention: Biopsy only
Number of subjects: 645
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lobe tumors
Number of subjects: 645
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe tumors
Number of subjects: 645
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal lobe tumors
Number of subjects: 645
Study 8387988 — intervention group
Group type: EXPERIMENTAL
Intervention: At least three favorable features (<40 years, high Karnofsky Performance Status, frontal tumors, total resection)
Number of subjects: 645
Study 3800032 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg orally every 6 h, beginning 24 h prior to bupivacaine administration
Number of subjects: 6
Study 3800032 — intervention group
Group type: COMPARATOR
Intervention: Control session (no propranolol)
Number of subjects: 6
Study 3800032 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 29265831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 166
Study 29265831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 166
Study 28714772 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families Durham (HFD) home visiting program
Number of subjects: 94
Study 28714772 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant attachment disorganization
Number of subjects: 94
Study 23834197 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 23834197 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers
Number of subjects: 0
Study 24195781 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the application of the Dutch guideline on assessment and treatment of suicidal behavior via a 1-day small interactive group training program supported by e-learning modules.
Number of subjects: 0
Study 24195781 — intervention group
Group type: COMPARATOR
Intervention: Usual dissemination of the guideline (internet, newsletter, books, publications, and congresses) without additional training.
Number of subjects: 0
Study 24195781 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the application of the guideline.
Number of subjects: 0
Study 21377738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stigma reduction program (N=34)
Number of subjects: 66
Study 21377738 — intervention group
Group type: COMPARATOR
Intervention: Newspaper reading group (N=32)
Number of subjects: 66
Study 18258368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2400 mg/day)
Number of subjects: 120
Study 18258368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16406190 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2500 mg)
Number of subjects: 46
Study 16406190 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (8 mg)
Number of subjects: 46
Study 16406190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (metformin and glimepiride)
Number of subjects: 46
Study 16406190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 14649343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam (2 mg) added to hyperbaric bupivacaine (15 mg) and buprenorphine (0.15 mg)
Number of subjects: 60
Study 14649343 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (15 mg) plus buprenorphine (0.15 mg)
Number of subjects: 60
Study 10992829 — intervention group
Group type: EXPERIMENTAL
Intervention: Local morphine (2 mg)
Number of subjects: 18
Study 10992829 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic morphine (2 mg)
Number of subjects: 18
Study 10992829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8616287 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Ottawa ankle rules
Number of subjects: 0
Study 8616287 — intervention group
Group type: COMPARATOR
Intervention: Standard radiographic examinations
Number of subjects: 0
Study 1399498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice a day for 2 weeks
Number of subjects: 12
Study 3908737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenampicillin (LAPC)
Number of subjects: 238
Study 3908737 — intervention group
Group type: COMPARATOR
Intervention: Talampicillin (TAPC)
Number of subjects: 238
Study 31235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol
Number of subjects: 47
Study 31235821 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 47
Study 30463829 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Number of subjects: 180
Study 30463829 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 180
Study 27250349 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment 1
Number of subjects: 40
Study 27250349 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment 2
Number of subjects: 40
Study 27250349 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 40
Study 24688254 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer's test
Number of subjects: 0
Study 24688254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film break up time (TBUT)
Number of subjects: 0
Study 24688254 — intervention group
Group type: EXPERIMENTAL
Intervention: Goblet cell density (GCD)
Number of subjects: 0
Study 24688254 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC)
Number of subjects: 0
Study 24688254 — intervention group
Group type: COMPARATOR
Intervention: Correlation coefficient for Schirmer's test
Number of subjects: 0
Study 24688254 — intervention group
Group type: COMPARATOR
Intervention: Correlation coefficient for TBUT
Number of subjects: 0
Study 24688254 — intervention group
Group type: COMPARATOR
Intervention: Correlation coefficient for Rose Bengal scores (RBS)
Number of subjects: 0
Study 24688254 — intervention group
Group type: COMPARATOR
Intervention: Correlation coefficient for GCD
Number of subjects: 0
Study 23009892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% rebamipide
Number of subjects: 308
Study 23009892 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 308
Study 23009892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 20382859 — intervention group
Group type: EXPERIMENTAL
Intervention: S. typhus vaccination
Number of subjects: 12
Study 18924053 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (weekly phone calls discussing physical activity)
Number of subjects: 42
Study 16118830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyamemazine (100-300 mg, administered at hourly intervals on day 1, then twice a day in decreasing doses)
Number of subjects: 89
Study 16118830 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg, administered at hourly intervals on day 1, then twice a day in decreasing doses)
Number of subjects: 89
Study 16118830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyamemazine
Number of subjects: 89
Study 11858980 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy trials conducted by EORTC STBSG
Number of subjects: 2500
Study 10359474 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study 10359474 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study 8749839 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 23
Study 8749839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8476892 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug immunotherapy with cyclosporine started before surgery (group 1)
Number of subjects: 30
Study 8476892 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 for 4 to 6 days after surgery with oral cyclosporine started between days 2 and 4 (group 2)
Number of subjects: 30
Study 8476892 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 (group 2)
Number of subjects: 30
Study 8476892 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 30
Study 3080012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 20
Study 3080012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (160 mg twice daily)
Number of subjects: 20
Study 30055597 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of assessment of performance of daily activities, defining a rehabilitation plan, and a follow-up home visit the day after discharge.
Number of subjects: 0
Study 27268572 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback with multiple exemplar training
Number of subjects: 0
Study 27268572 — intervention group
Group type: COMPARATOR
Intervention: Performance feedback without generality programming
Number of subjects: 0
Study 27268572 — intervention group
Group type: COMPARATOR
Intervention: Weekly writing practice alone
Number of subjects: 0
Study 24493100 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure (BP) lowering (systolic BP goal of less than 120 mm Hg)
Number of subjects: 2977
Study 24493100 — intervention group
Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 2977
Study 24493100 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure (BP) lowering (systolic BP goal of less than 140 mm Hg)
Number of subjects: 2977
Study 24493100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2977
Study 22810111 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐CD
Number of subjects: 25
Study 22810111 — intervention group
Group type: COMPARATOR
Intervention: PTBD
Number of subjects: 25
Study 20818876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 66
Study 20818876 — intervention group
Group type: COMPARATOR
Intervention: Control (wellness education and stretching)
Number of subjects: 66
Study 18923307 — intervention group
Group type: EXPERIMENTAL
Intervention: PUMC classification
Number of subjects: 62
Study 18923307 — intervention group
Group type: COMPARATOR
Intervention: Lenke classification
Number of subjects: 62
Study 15811593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 21
Study 15811593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS I
Number of subjects: 26
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS II
Number of subjects: 26
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS III
Number of subjects: 26
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload at MLSS III
Number of subjects: 26
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload at MLSS I
Number of subjects: 26
Study 12627312 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload at MLSS II
Number of subjects: 26
Study 9428875 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP (100 micrograms.kg‐1.min‐1)
Number of subjects: 102
Study 9428875 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 102
Study 8036656 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets
Number of subjects: 350
Study 8036656 — intervention group
Group type: COMPARATOR
Intervention: Non-treated nets
Number of subjects: 350
Study 2972209 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered combined hormones
Number of subjects: 110
Study 2972209 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous hormones
Number of subjects: 110
Study 2972209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 30176379 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Number of subjects: 20
Study 30176379 — intervention group
Group type: COMPARATOR
Intervention: Athletic tape (AT)
Number of subjects: 20
Study 28929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist bromocriptine
Number of subjects: 20
Study 28929131 — intervention group
Group type: COMPARATOR
Intervention: Dopamine D2 receptor availability assessed with PET-[18F]fallypride
Number of subjects: 20
Study 25948722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 43
Study 25948722 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 43
Study 25948722 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study 24143890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐reminiscence therapy (six sessions of weekly, individual psychotherapy)
Number of subjects: 0
Study 24143890 — intervention group
Group type: COMPARATOR
Intervention: Usual care (support from the youth mental health service according to usual procedures)
Number of subjects: 0
Study 21165702 — intervention group
Group type: EXPERIMENTAL
Intervention: DAO capsules
Number of subjects: 39
Study 21165702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18438933 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training program for the musculature of the shoulder, held twice a week for 2 months.
Number of subjects: 60
Study 18438933 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list).
Number of subjects: 60
Study 17070254 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 shock waves per minute
Number of subjects: 100
Study 17070254 — intervention group
Group type: COMPARATOR
Intervention: 120 shock waves per minute
Number of subjects: 100
Study 12859304 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Patients received a tape containing 20 words played before the start of anaesthesia.
Number of subjects: 60
Study 12859304 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Patients received propofol at a calculated concentration associated with loss of consciousness (LOC) and a tape was played during this state.
Number of subjects: 60
Study 12859304 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Group (RG) - Patients did not receive the tape.
Number of subjects: 60
Study 11063952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg orally twice a day)
Number of subjects: 698
Study 11063952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg orally 3 times a day)
Number of subjects: 698
Study 11063952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 698
Study 9033154 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC) combined with community-based case management
Number of subjects: 0
Study 9033154 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8500233 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1427
Study 3328905 — intervention group
Group type: EXPERIMENTAL
Intervention: True Auriculo-electropuncture (AEP)
Number of subjects: 16
Study 3328905 — intervention group
Group type: COMPARATOR
Intervention: False Auriculo-electropuncture (control)
Number of subjects: 16
Study 28982550 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3000 mg/d)
Number of subjects: 134
Study 28982550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 27046546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based anti-smoking game
Number of subjects: 0
Study 27046546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based anti-smoking game with avatar resembling self
Number of subjects: 0
Study 27046546 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-smoking game without avatar)
Number of subjects: 0
Study 26717658 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (6 ml/kg as a single bolus over 10-15 min, maximum of 2 boluses)
Number of subjects: 44
Study 26717658 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 44
Study 26717658 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 44
Study 23114184 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-degree reverse Trendelenburg position (RTP)
Number of subjects: 64
Study 23114184 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position (HP)
Number of subjects: 64
Study 20606833 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐ACEIs (enalapril, lisinopril, ramipril)
Number of subjects: 120
Study 20606833 — intervention group
Group type: COMPARATOR
Intervention: p‐ACEIs (fosinopril)
Number of subjects: 120
Study 17822879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (15 microg/ml)
Number of subjects: 40
Study 17822879 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (12.5 microg/ml)
Number of subjects: 40
Study 16054717 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 41
Study 16054717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 12842527 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration plus modified ultrafiltration during CPB
Number of subjects: 30
Study 12842527 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB without ultrafiltration
Number of subjects: 30
Study 9887063 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide (800 micrograms twice daily for 4 weeks)
Number of subjects: 11
Study 9887063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (various concentrations)
Number of subjects: 11
Study 8777366 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A with 2.5% glucose and 70 mmol Na+
Number of subjects: 24
Study 8777366 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution B with 5.5% glucose and 100 mmol Na+
Number of subjects: 24
Study 8777366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 24
Study 2057198 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 76
Study 2057198 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 76
Study 7173300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (Nicorette 4 mg)
Number of subjects: 8
Study 7173300 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 8
Study 31122995 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive medical and social intervention
Number of subjects: 1600
Study 31122995 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1600
Study 30307821 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise (CONT) at 70% HRpeak for 60 min/day over 2 weeks
Number of subjects: 31
Study 30307821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (INT) with 3 min at 90% HRpeak and 3 min at 50% HRpeak for 60 min/day over 2 weeks
Number of subjects: 31
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of animal source foods (ASF)
Number of subjects: 928